[A23-42] Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2023
Project no.:
A23-42
Commission:
Commission awarded on 11.05.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Pre-exposure prophylaxis for COVID-19 in adults and adolescents aged 12 years and older and with a body weight of at least 40 kg
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-111 | Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A23-96 | Tixagevimab/cilgavimab (pre-exposure prophylaxis of COVID-19) – Addendum to Commission A23-42 | Commission completed |
Federal Joint Committee (G-BA)
2023-11-02 A G-BA decision was published.